Bacil Pharma Ltd — Board Meeting, 26-05-2025: Board Meeting

Bacil Pharma Limited has announced a board meeting that approved the audited financial results for the quarter and half-year ending March 31, 2025. The company reported total revenue of ₹66.14 lakh for the year, largely from other income, with expenses at ₹25.39 lakh resulting in a profit after tax of ₹40.05 lakh. Investments increased significantly to ₹21.36 Cr from ₹0.61 Cr the previous year, while cash and cash equivalents rose to ₹2.86 Cr. The auditor issued an unmodified opinion but highlighted outstanding loans and advances lacking confirmation, leaving recoverability uncertain. The company remains focused on asset growth and operational profitability.